Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..
2017.
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.
Pyenson NC, Gayvert K, Varble A, Elemento O, Marraffini LA.
2017.
Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.. Cell Host Microbe. 22(3):343-353.e3.
Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..
2017.
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.
Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al..
2017.
The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLeah B, A Van den Heuvel PJ, Lev A, Garnett MJ, McDermott U et al..
2017.
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.. PLoS One. 12(8):e0180541.
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLeah B, A Van den Heuvel PJ, Lev A, Garnett MJ, McDermott U et al..
2017.
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.. PLoS One. 12(8):e0180541.
Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.
2017.
A Computational Approach for Identifying Synergistic Drug Combinations.. PLoS Comput Biol. 13(1):e1005308.
Lis R, Karrasch CC, Poulos MG, Kunar B, Redmond D, Duran JGBarcia, Badwe CR, Schachterle W, Ginsberg M, Xiang J et al..
2017.
Conversion of adult endothelium to immunocompetent haematopoietic stem cells.. Nature. 545(7655):439-445.
Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..
2017.
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.
Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..
2017.
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.
Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick A, Elemento O.
2017.
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.. Cancer Res. 77(8):1818-1830.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM et al..
2017.
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. Cancer Discov. 7(8):868-883.
Romanel A, Zhang T, Elemento O, Demichelis F.
2017.
EthSEQ: ethnicity annotation from whole exome sequencing data.. Bioinformatics. 33(15):2402-2404.
Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J.
2017.
Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.. Nucleic Acids Res. 45(10):5639-5652.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..
2017.
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.